Winning Gold Medal at Geneva Exhibition of Inventions 2025: Revolutionizing Radioligand Therapy
- eymonwu
- May 5
- 1 min read
Updated: Oct 13
L’Ord’invent Limited (an InnoHK@HKU spin-off) and ZERO Biotech Limited have won a gold medal at The International Exhibition of Inventions Geneva 2025 for their breakthrough platform improving the administration of Lutetium-177 DOTATOC therapy (PRRT) for neuroendocrine tumors (NETs).
Best in Precision and Least in Side Effects
This innovative system enhances precision in delivering targeted radiotherapy, minimizing side effects and improving patient outcomes. Already used to treat 15+ patients (supported by the Li Ka Shing Foundation’s “Love Can Help” program), it solves critical challenges in radioactive drug handling.
Success of University Spinoff-Industry Partnership
The award highlights the HKU-ZERO Biotech partnership’s success in advancing radiopharmaceutical innovation—paving the way for future global patient benefits.
The International Exhibition of Inventions Geneva, a premier global event, showcases top healthcare and tech innovations from 40+ countries.
Comments